| Project Owner | | Project City | State | Years | Value | | IQHQ Incorporated | Boston Brownfield Fenway Life Science Research Center | Boston | MA | 2023-25 | $1,000 million |
| Eli Lilly & Company | Boston Brownfield “Lilly Institute For Genetic Medicine” Facility | Boston | MA | 2022-24 | $700 million |
| Takeda Pharmaceuticals USA Incorporated | Cambridge Brownfield Oncology, Hematology, Neuroscience, Gastroenterology R&D | Cambridge | MA | 2022-26 | $700 million |
| Ivanhoe Cambridge | Boston (Brighton) Brownfield Forum 60 Guest Street Laboratory | Boston | MA | 2022-25 | $545 million |
| AstraZeneca PLC | Cambridge Brownfield AstraZeneca Oncology & Biologics R&D Center | Cambridge | MA | 2024-26 | $533.5 million |
| BioMed Realty Trust Incorporated | Somerville BF Life Science “Assembly Innovation Park” 188 Assembly Drive | Somerville | MA | 2022-25 | $514 million |
| Bristol-Myers Squibb Company | Cambridge Crossing Grassroot 250 Water St R&D Laboratory Building | Cambridge | MA | 2020-24 | $450 million |
| Greystar Real Estate LLC | Somerville Brownfield 74M Life Science Building | Somerville | MA | 2022-24 | $420 million |
| Sanofi US | Cambridge Crossing (“CX”) Grassroot Genetic Rare Disease R&D Laboratory Parcel G | Cambridge | MA | 2019-22 | $400 million |
| Vertex Pharmaceuticals Incorporated | Boston Jeffrey Leiden Center For Cell and Genetic Therapies Addition (Leiden II) | Boston | MA | 2023-25 | $400 million |